株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

乳癌:パイプライン製品の分析

Breast Cancer - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 229715
出版日 ページ情報 英文 3149 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
乳癌:パイプライン製品の分析 Breast Cancer - Pipeline Review, H2 2016
出版日: 2016年12月21日 ページ情報: 英文 3149 Pages
概要

乳癌は、乳腺細胞から発症する癌の一種です。通常、乳管の内壁や小葉から始まります。乳癌の危険因子として、年齢、初潮が早い、閉経が遅い、太り過ぎ、ホルモン補充療法、経口避妊薬の使用、アルコール摂取などが挙げられます。症状は、乳房のしこり、乳房の大きさや形状の変化、乳頭からの分泌物などです。治療には、放射線、腫瘍摘出手術、乳腺切除術、化学療法、ホルモン療法などが含まれます。

当レポートでは、乳癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

乳癌の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 未確認段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8871IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Breast Cancer - Pipeline Review, H2 2016, provides an overview of the Breast Cancer (Oncology) pipeline landscape.

Breast cancer is a cancer that develops from breast cells. Breast cancer usually starts off in the inner lining of milk ducts or the lobules that supply them with milk. Risk factors of breast cancer includes age, beginning of periods before the age of twelve or going through menopause after the age of fifty-five, being overweight, using hormone replacement therapy, consumption of birth control pills and consumption of alcohol. Symptoms include a lump in the breast, a change in size or shape of the breast or discharge from a nipple. Treatment includes radiation, lumpectomy, mastectomy, chemotherapy and hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Breast Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Breast Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Breast Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 45, 158, 167, 2, 13, 474, 96 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 16, 17, 1, 150 and 44 molecules, respectively.

Breast Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Breast Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Breast Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Breast Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Breast Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Breast Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Breast Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Breast Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Breast Cancer Overview
  • Therapeutics Development
  • Breast Cancer - Therapeutics under Development by Companies
  • Breast Cancer - Therapeutics under Investigation by Universities/Institutes
  • Breast Cancer - Pipeline Products Glance
  • Breast Cancer - Products under Development by Companies
  • Breast Cancer - Products under Investigation by Universities/Institutes
  • Breast Cancer - Companies Involved in Therapeutics Development
  • Breast Cancer - Therapeutics Assessment
  • Drug Profiles
  • Breast Cancer - Dormant Projects
  • Breast Cancer - Discontinued Products
  • Breast Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Breast Cancer, H2 2016
  • Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Development by Companies, H2 2016 (Contd..14)
  • Number of Products under Development by Companies, H2 2016 (Contd..15)
  • Number of Products under Development by Companies, H2 2016 (Contd..16)
  • Number of Products under Development by Companies, H2 2016 (Contd..17)
  • Number of Products under Development by Companies, H2 2016 (Contd..18)
  • Number of Products under Development by Companies, H2 2016 (Contd..19)
  • Number of Products under Development by Companies, H2 2016 (Contd..20)
  • Number of Products under Development by Companies, H2 2016 (Contd..21)
  • Number of Products under Development by Companies, H2 2016 (Contd..22)
  • Number of Products under Development by Companies, H2 2016 (Contd..23)
  • Number of Products under Development by Companies, H2 2016 (Contd..24)
  • Number of Products under Development by Companies, H2 2016 (Contd..25)
  • Number of Products under Development by Companies, H2 2016 (Contd..26)
  • Number of Products under Development by Companies, H2 2016 (Contd..27)
  • Number of Products under Development by Companies, H2 2016 (Contd..28)
  • Number of Products under Development by Companies, H2 2016 (Contd..29)
  • Number of Products under Development by Companies, H2 2016 (Contd..30)
  • Number of Products under Development by Companies, H2 2016 (Contd..31)
  • Number of Products under Development by Companies, H2 2016 (Contd..32)
  • Number of Products under Development by Companies, H2 2016 (Contd..33)
  • Number of Products under Development by Companies, H2 2016 (Contd..34)
  • Number of Products under Development by Companies, H2 2016 (Contd..35)
  • Number of Products under Development by Companies, H2 2016 (Contd..36)
  • Number of Products under Development by Companies, H2 2016 (Contd..37)
  • Number of Products under Development by Companies, H2 2016 (Contd..38)
  • Number of Products under Development by Companies, H2 2016 (Contd..39)
  • Number of Products under Development by Companies, H2 2016 (Contd..40)
  • Number of Products under Development by Companies, H2 2016 (Contd..41)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..6)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..7)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..8)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Development by Companies, H2 2016 (Contd..21)
  • Products under Development by Companies, H2 2016 (Contd..22)
  • Products under Development by Companies, H2 2016 (Contd..23)
  • Products under Development by Companies, H2 2016 (Contd..24)
  • Products under Development by Companies, H2 2016 (Contd..25)
  • Products under Development by Companies, H2 2016 (Contd..26)
  • Products under Development by Companies, H2 2016 (Contd..27)
  • Products under Development by Companies, H2 2016 (Contd..28)
  • Products under Development by Companies, H2 2016 (Contd..29)
  • Products under Development by Companies, H2 2016 (Contd..30)
  • Products under Development by Companies, H2 2016 (Contd..31)
  • Products under Development by Companies, H2 2016 (Contd..32)
  • Products under Development by Companies, H2 2016 (Contd..33)
  • Products under Development by Companies, H2 2016 (Contd..34)
  • Products under Development by Companies, H2 2016 (Contd..35)
  • Products under Development by Companies, H2 2016 (Contd..36)
  • Products under Development by Companies, H2 2016 (Contd..37)
  • Products under Development by Companies, H2 2016 (Contd..38)
  • Products under Development by Companies, H2 2016 (Contd..39)
  • Products under Development by Companies, H2 2016 (Contd..40)
  • Products under Development by Companies, H2 2016 (Contd..41)
  • Products under Development by Companies, H2 2016 (Contd..42)
  • Products under Development by Companies, H2 2016 (Contd..43)
  • Products under Development by Companies, H2 2016 (Contd..44)
  • Products under Development by Companies, H2 2016 (Contd..45)
  • Products under Development by Companies, H2 2016 (Contd..46)
  • Products under Development by Companies, H2 2016 (Contd..47)
  • Products under Development by Companies, H2 2016 (Contd..48)
  • Products under Development by Companies, H2 2016 (Contd..49)
  • Products under Development by Companies, H2 2016 (Contd..50)
  • Products under Development by Companies, H2 2016 (Contd..51)
  • Products under Development by Companies, H2 2016 (Contd..52)
  • Products under Development by Companies, H2 2016 (Contd..53)
  • Products under Development by Companies, H2 2016 (Contd..54)
  • Products under Development by Companies, H2 2016 (Contd..55)
  • Products under Development by Companies, H2 2016 (Contd..56)
  • Products under Development by Companies, H2 2016 (Contd..57)
  • Products under Development by Companies, H2 2016 (Contd..58)
  • Products under Development by Companies, H2 2016 (Contd..59)
  • Products under Development by Companies, H2 2016 (Contd..60)
  • Products under Development by Companies, H2 2016 (Contd..61)
  • Products under Development by Companies, H2 2016 (Contd..62)
  • Products under Development by Companies, H2 2016 (Contd..63)
  • Products under Development by Companies, H2 2016 (Contd..64)
  • Products under Development by Companies, H2 2016 (Contd..65)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..6)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..8)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..9)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..10)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..11)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..12)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..13)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..14)
  • Breast Cancer - Pipeline by 3-D Matrix Ltd, H2 2016
  • Breast Cancer - Pipeline by 3-V Biosciences Inc, H2 2016
  • Breast Cancer - Pipeline by 3SBio Inc, H2 2016
  • Breast Cancer - Pipeline by 4SC AG, H2 2016
  • Breast Cancer - Pipeline by A&G Pharmaceutical Inc, H2 2016
  • Breast Cancer - Pipeline by AB Science SA, H2 2016
  • Breast Cancer - Pipeline by AbbVie Inc, H2 2016
  • Breast Cancer - Pipeline by AbGenomics International Inc, H2 2016
  • Breast Cancer - Pipeline by Acceleron Pharma Inc, H2 2016
  • Breast Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
  • Breast Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Breast Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016
  • Breast Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016
  • Breast Cancer - Pipeline by Aduro BioTech Inc, H2 2016
  • Breast Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016
  • Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016
  • Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corp, H2 2016
  • Breast Cancer - Pipeline by Advantagene Inc, H2 2016
  • Breast Cancer - Pipeline by Advaxis Inc, H2 2016
  • Breast Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016
  • Breast Cancer - Pipeline by Aegis Therapeutics LLC, H2 2016
  • Breast Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016
  • Breast Cancer - Pipeline by Aerpio Therapeutics Inc, H2 2016
  • Breast Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016
  • Breast Cancer - Pipeline by Affichem SA, H2 2016
  • Breast Cancer - Pipeline by Agenus Inc, H2 2016
  • Breast Cancer - Pipeline by Agilvax Inc, H2 2016
  • Breast Cancer - Pipeline by Aileron Therapeutics Inc, H2 2016
  • Breast Cancer - Pipeline by Alchemia Ltd, H2 2016
  • Breast Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016
  • Breast Cancer - Pipeline by Alissa Pharma, H2 2016
  • Breast Cancer - Pipeline by Almac Discovery Ltd, H2 2016
  • Breast Cancer - Pipeline by Alteogen Inc, H2 2016
  • Breast Cancer - Pipeline by Amarna Therapeutics BV, H2 2016
  • Breast Cancer - Pipeline by Ambrx Inc, H2 2016
  • Breast Cancer - Pipeline by American Gene Technologies International Inc, H2 2016
  • Breast Cancer - Pipeline by Amgen Inc, H2 2016
  • Breast Cancer - Pipeline by Ampio Pharmaceuticals Inc, H2 2016
  • Breast Cancer - Pipeline by Amplyx Pharmaceuticals Inc, H2 2016
  • Breast Cancer - Pipeline by Angion Biomedica Corp, H2 2016
  • Breast Cancer - Pipeline by ANP Technologies Inc, H2 2016
  • Breast Cancer - Pipeline by AntiCancer Inc, H2 2016
  • Breast Cancer - Pipeline by Antigen Express Inc, H2 2016
  • Breast Cancer - Pipeline by Antoxis Ltd, H2 2016
  • Breast Cancer - Pipeline by Aphios Corp, H2 2016
  • Breast Cancer - Pipeline by APIM Therapeutics AS, H2 2016
  • Breast Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016
  • Breast Cancer - Pipeline by Aravive Biologics Inc, H2 2016
  • Breast Cancer - Pipeline by ARMO Biosciences Inc, H2 2016
  • Breast Cancer - Pipeline by Armour Therapeutics Inc, H2 2016
  • Breast Cancer - Pipeline by Arno Therapeutics Inc, H2 2016
  • Breast Cancer - Pipeline by ArQule Inc, H2 2016
  • Breast Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016
  • Breast Cancer - Pipeline by Arvinas Inc, H2 2016
  • Breast Cancer - Pipeline by Asana BioSciences LLC, H2 2016
  • Breast Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016
  • Breast Cancer - Pipeline by AskAt Inc, H2 2016
  • Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016
  • Breast Cancer - Pipeline by Astellas Pharma Inc, H2 2016
  • Breast Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016
  • Breast Cancer - Pipeline by AstraZeneca Plc, H2 2016

List of Figures

  • Number of Products under Development for Breast Cancer, H2 2016
  • Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top